PedAM
Pediatric Disease Annotations & Medicines
| Disease | autonomic dysfunction |
| Phenotype | C0037928|spinal cord disease |
| Sentences | 1 |
| PubMedID- 26009577 | They will be eligible if all of the following apply at the time of randomisation:age 1 year or overdiagnosis of either acute first onset transverse myelitis (using the tm consortium working group 2002 criteria6)—patients must fulfil all of the following criteria:sensory, motor or autonomic dysfunction attributable to spinal cord diseasebilateral signs and/or symptoms (not necessarily symmetric)sensory level (except in young children <5 years where this is difficult to evaluate)lack of mri brain criteria consistent with multiple sclerosis20progression to nadir between 4 h and 21 daysor first presentation of neuromyelitis optica (using standardised criteria21)—patients must fulfil both absolute criteria:optic neuritisacute myelitisplus two out of three supportive criteria (as aqp4 is often not available acutely, only the first two supportive criteria would be applied):brain mri not meeting criteria for ms at disease onsetspinal cord mri with contiguous t2-weighted signal abnormality extending over three or more vertebral segments, indicating a relatively large lesion in the spinal cordaquaporin 4 igg seropositive statusasia impairment score of a-crandomisation to occur no later than day 5 of steroids, and, if definitely known, within 21 days from symptom onset.give assent (8–16 years)/consent to participate in the trial. |
Page: 1